How Long People Stay on Inclisiran, Evolocumab or Alirocumab for Heart Disease
Looks at how long adults keep taking these cholesterol-lowering medicines in routine care.
Plain-language title generated from the registry record
Registry title: A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Key facts
- Where
- Basel, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07543731, who can take part
Where in Switzerland
- NovartisBasel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07543731
- Record updated
- 15 July 2026
- Original description
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.Read full original descriptionShow less
Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Inclusion: A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period; Age ≥18 years at index date; With at least 12 months data availability prior to index date.
Exclusion: Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.